SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023
May 10, 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, May 10, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device
May 09, 2023 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, May 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
March 30, 2023 19:23 ET
|
SeaStar Medical Holding Corporation
DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
March 16, 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, March 16, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023
March 15, 2023 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, March 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
February 24, 2023 08:05 ET
|
SeaStar Medical Holding Corporation
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
February 15, 2023 16:01 ET
|
SeaStar Medical Holding Corporation
The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD’s ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation ...
IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY
February 14, 2023 09:15 ET
|
IR-Med, Inc.
The study will expand to Rabin Medical Center (RMC), in parallel to Beit-Rivka, turning the study to a double center usability study. Rosh Pinna, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) --...
IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device
August 30, 2022 09:15 ET
|
IR-Med, Inc.
Rosh Pinna, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative medical device company that is developing non-invasive, real-time detection devices...
IR-Med To Initiate Useability Study of its PressureSafe Device
June 23, 2022 09:15 ET
|
IR-Med, Inc.
Rosh Pinna, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR)...